Search

Your search keyword '"Kapina M"' showing total 79 results

Search Constraints

Start Over You searched for: Author "Kapina M" Remove constraint Author: "Kapina M"
79 results on '"Kapina M"'

Search Results

3. HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women

5. Wastewater Surveillance of SARS-CoV-2 in Zambia: An Early Warning Tool

8. Evaluating the impact of COVID-19 on routine childhood immunizations coverage in Zambia.

11. Increased Sensitization of Health Workers Leading to Detection of Unintended Cases of Acute Flaccid Paralysis: A Case of a 'Konzo' Outbreak in Western Zambia

14. A Retrospective Analysis of Lessons Learned and Perspectives on Expansion of Verbal Autopsy Implementation in Zambia, 2023.

15. Polygenic TB control and the sequence of innate/adaptive immune responses to infection: MHC-II alleles determine the size of the S100A8/9-producing neutrophil population.

16. An assessment of excess mortality during the COVID-19 pandemic, a retrospective post-mortem surveillance in 12 districts - Zambia, 2020-2022.

17. Detection of Human Adenovirus and Rotavirus in Wastewater in Lusaka, Zambia: Demonstrating the Utility of Environmental Surveillance for the Community.

18. Efficacy of macozinone in mice with genetically diverse susceptibility to Mycobacterium tuberculosis infection.

19. Observational study on the characteristics of COVID-19 transmission dynamics during the first wave of the epidemic in Lusaka, Zambia.

20. Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits in Zambia: A repeated cross-sectional survey, 2021-2022.

21. COVID-19 mortality sentinel surveillance at a tertiary referral hospital in Lusaka, Zambia, 2020-2021.

22. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.

23. Characteristics of cases and deaths arising from SARS-CoV-2 infection in Zambia: March 2020 to April 2021.

24. The H2-A Class II molecule α/β-chain cis- mismatch severely affects cell surface expression, selection of conventional CD4 + T cells and protection against TB infection.

25. Spatial factors for COVID-19 associated community deaths in an urban area of Lusaka, Zambia: an observational study.

26. Comparison of COVID-19 Pandemic Waves in 10 Countries in Southern Africa, 2020-2021.

27. Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case-control study in Lusaka, Zambia.

28. COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant-Zambia, December 2021.

29. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers-Zambia, July 2020.

30. SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020.

31. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey.

32. Prolonged infection triggered by dormant Mycobacterium tuberculosis: Immune and inflammatory responses in lungs of genetically susceptible and resistant mice.

33. Zambia field epidemiology training program: strengthening health security through workforce development.

34. Konzo outbreak in the Western Province of Zambia.

35. A Multisectoral Emergency Response Approach to a Cholera Outbreak in Zambia: October 2017-February 2018.

36. Cholera Epidemic - Lusaka, Zambia, October 2017-May 2018.

37. Human-animal anthrax outbreak in the Luangwa valley of Zambia in 2011.

38. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

39. [A locus involved in tuberculosis infection control in mice locates in the proximal part of the H2 complex].

40. [Development of pulmonary chlamydia infection in inbred mice lines differentiated by genetically determinated sensitivity to tuberculosis infection].

41. HIV incidence rates and risk factors for urban women in Zambia: preparing for a microbicide clinical trial.

42. [Experimental approaches to designing vaccines against tuberculous infection reactivation].

43. CD4 T cells producing IFN-gamma in the lungs of mice challenged with mycobacteria express a CD27-negative phenotype.

44. [Significance of molecular genetic and immunological techniques in risk groups and in children with tuberculosis].

45. [Anti-tuberculous IgE antibodies. I. Immunodominant antigens].

46. [Tuberculous IgE antibodies. Part II. Study of its concentrations in different forms of tuberculosis].

47. [Improving the efficacy of tuberculosis immunodiagnosis using anti-human IgG monoclonal antibodies].

48. [Study of characteristics of the antigen structure of different mycobacteria (epitope mapping) with monoclonal antibodies].

49. [Detection of antituberculosis antibodies and antigens by enzyme immunoassay in young and preschool children suffering from tuberculosis].

50. [Serological and immunochemical properties of carbohydrate-containing fraction from mycobacterium tuberculosis H37Rv].

Catalog

Books, media, physical & digital resources